Epeña

What is Epeña?

Epeña refers to the psychoactive snuff prepared from the inner-bark resin of several Virola trees (family Myristicaceae) of the Amazon, and to the trees themselves. The reddish resin is rich in tryptamine alkaloids and has been used for centuries by indigenous peoples of the north-western Amazon and Orinoco regions.

Traditional & Modern Uses

Among peoples such as the Yanomami and various groups of the Colombian and Venezuelan Amazon, the resin is scraped, dried and processed — often with the ash of other plants — into a fine snuff that is blown forcefully into the nostrils through a tube, sometimes by another person. The snuff (called epená, yakee, yopo or by other local names) is used by shamans for healing, divination and contact with the spirit world. The experience is rapid, powerful and physically demanding.

Beyond the snuff, the Virola resin has a second, quieter ethnobotanical life: applied topically to the skin as an antifungal, a use documented across roughly fourteen Amazonian groups in four countries ^{6Reference 6Plotkin MJ · 1990ReviewVirola: a promising genus for ethnopharmacological investigation — review of antifungal ethnobotanyView study →}. It is arguably the plant’s best-attested non-psychoactive traditional use, and — unlike the snuff — one that maps onto a plausible pharmacological mechanism (see below).

Phytochemistry

The active compounds of the snuff are indole alkaloids of the tryptamine and β-carboline classes, concentrated in the reddish bark resin. The principal and marker compound is 5-MeO-DMT, one of the most potent psychedelics known, accompanied by lesser amounts of N,N-DMT and N-monomethyltryptamine, together with the β-carboline 2-methyl-6-methoxy-1,2,3,4-tetrahydro-beta-carboline ^{1Reference 1Agurell S et al. · 1969Alkaloids in certain species of Virola and other South American plants of ethnopharmacologic interest — chemical isolation studyView study →}. In Virola theiodora, the species most used for snuff, the resin can be exceptionally alkaloid-rich, with 5-MeO-DMT alone reported around 8% and total alkaloids in some prepared snuffs reaching about 11% ^{1Reference 1Agurell S et al. · 1969Alkaloids in certain species of Virola and other South American plants of ethnopharmacologic interest — chemical isolation studyView study →}. The exact alkaloid profile varies considerably — by orders of magnitude — between species, region and preparation ^{3Reference 3McKenna DJ et al. · 1984Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: Constituents of orally-active Myristicaceous hallucinogens — analytical/ethnopharmacology studyView study →}.

Beyond the alkaloids, the wider Virola genus carries a substantial non-psychoactive chemistry that underlies all of its preclinical pharmacology: lignans and 8.O.4′-neolignans (grandisin, surinamensin, otobaphenol), flavonoids and phenolic acids (epicatechin, eriodictyol, catechin, gallic acid, rutin), and essential-oil sesquiterpenes (nerolidol) ^{37Reference 37González-Rodríguez M et al. · 2021ReviewPharmacological Extracts and Molecules from Virola Species: Traditional Uses, Phytochemistry, and Biological Activity — reviewView study →}. These are largely documented in other Virola species (V. surinamensis, V. oleifera, V. elongata, V. sebifera) rather than the snuff source V. theiodora, and are pharmacologically and legally distinct from the tryptamine snuff.

Constituent Summary

Figures are approximate percentages of the dried bark resin from classic isolation work on Virola theiodora; the minor tryptamines and the β-carboline are present in much smaller, generally unquantified amounts, and the profile differs by species and source. † marks the marker constituent that characterises Virola snuff (epena).

Pharmacology & Research

Epeña occupies two distinct evidentiary worlds. Its marker alkaloid, 5-MeO-DMT, is now the subject of early human clinical trials as a rapid-acting antidepressant — the only genuinely human-tier evidence in this monograph ^{21,22,23,24Reference 21Rucker JJ et al. · 2024RCTPhase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants — randomised controlled trialView study →Reference 22Reckweg JT et al. · 2025Clinical trialEvaluation of the peak experience scale as a rapid assessment tool for the strength of a psychoactive experience with 5-MeO-DMT — clinical studyView study →Reference 23Wallace LM et al. · 2026Meta-analysisEfficacy of N, N-dimethyltryptamine (DMT) psychedelic therapy for substance misuse: A systematic review and meta-analysis — systematic review and meta-analysisView study →Reference 24Marazziti D et al. · 2026ReviewPsychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations — reviewView study →}. The rest of the Virola genus (Myristicaceae) carries a compact preclinical literature — roughly forty studies — built on its non-psychoactive chemistry of lignans, neolignans, flavonoids and phenolic acids, showing consistent gastroprotective, antioxidant and anti-inflammatory activity in rodents plus antifungal, antiparasitic and antiproliferative signals in vitro ^{7,8,9,10,11,12,13,14,16,17,18,19,25,26,27,28,29,30,31,37Reference 7Hiruma-Lima CA et al. · 2009AnimalAntiulcerogenic action of ethanolic extract of the resin from Virola surinamensis Warb. (Myristicaceae) — in vivo rodent studyView study →Reference 8Pereira AC et al. · 2017AnimalGastroprotective activity of the resin from Virola oleifera — in vivo mouse studyView study →Reference 9Almeida GVB et al. · 2019AnimalChemical characterization and evaluation of gastric antiulcer properties of the hydroethanolic extract of the stem bark of Virola elongata (Benth.) Warb — in vivo rodent studyView study →Reference 10Rezende KR et al. · 2005In vitroAntioxidant activity of aryltetralone lignans and derivatives from Virola sebifera (Aubl.) — in vitro studyView study →Reference 11Lemeshko VV et al. · 2003In vitroThe natural antioxidant otobaphenol delays the permeability transition of mitochondria and induces their aggregation — in vitro studyView study →Reference 12Dos Santos Corrêa A et al. · 2018In vitroVirola oleifera-capped gold nanoparticles showing radical-scavenging activity and low cytotoxicity — in vitro studyView study →Reference 13Coutinho PN et al. · 2017AnimalChronic administration of antioxidant resin from Virola oleifera attenuates atherogenesis in LDLr — in vivo mouse studyView study →Reference 14Bôa IS et al. · 2015AnimalResin from Virola oleifera Protects Against Radiocontrast-Induced Nephropathy in Mice — in vivo mouse studyView study →Reference 16Carvalho AA et al. · 2010AnimalAntinociceptive and antiinflammatory activities of grandisin extracted from Virola surinamensis — in vivo mouse studyView study →Reference 17Carvalho JC et al. · 1999AnimalAnti-inflammatory activity of flavone and some of its derivates from Virola michelli Heckel — in vivo rat studyView study →Reference 18Di Serio BF et al. · 2024In vitroPhytochemistry and Evaluation of the Anti-Inflammatory Activity of the Hydroethanolic Extract of Virola elongata (Benth.) WarbView study →Reference 19Zacchino S et al. · 1998In vitroIn vitro studies on mode of action of antifungal 8.O.4’-neolignans occurring in certain species of Virola and related genera of Myristicaceae — in vitro studyView study →Reference 25Barata LE et al. · 2000In vitroAnti-leishmanial activity of neolignans from Virola species and synthetic analogues — in vitro and in vivo studyView study →Reference 26Veiga A et al. · 2017In vitroLeishmania amazonensis and Leishmania chagasi: In vitro leishmanicide activity of Virola surinamensis (rol.) warb — in vitro studyView study →Reference 27Lopes NP et al. · 1998In vitroFlavonoids and lignans from Virola surinamensis twigs and their in vitro activity against Trypanosoma cruzi — in vitro studyView study →Reference 28Paes SS et al. · 2023In vitroPaes SS, et al. (2023). (-)-5-Demethoxygrandisin B a New Lignan from Virola surinamensis (Rol.) Warb. Leaves: Evaluation of the Leishmanicidal Activity by In Vitro and In Silico Approaches — in vitro study. Pharmaceutics. 15(9). https://pubmed.ncbi.nlm.nih.gov/37765261/View study →Reference 29Denny C et al. · 2008In vitroAntiproliferative properties of polyketides isolated from Virola sebifera leaves — in vitro studyView study →Reference 30Anunciação TAD et al. · 2020In vitroIn vitro and in vivo inhibition of HCT116 cells by essential oils from bark and leaves of Virola surinamensis (Rol. ex Rottb.) Warb. (Myristicaceae) — in vitro and in vivo mouse studyView study →Reference 31Francisco V et al. · 2021In vitroEvaluation of Virola oleifera activity in musculoskeletal pathologies: Inhibition of human multiple myeloma cells proliferation and combination therapy with dexamethasone or bortezomib — in vitro studyView study →Reference 37González-Rodríguez M et al. · 2021ReviewPharmacological Extracts and Molecules from Virola Species: Traditional Uses, Phytochemistry, and Biological Activity — reviewView study →}. Crucially, the human trials use a synthetic, isolated form of 5-MeO-DMT delivered by nasal spray or inhalation — pharmacologically and legally distinct from the highly variable ceremonial snuff ^{3,21Reference 3McKenna DJ et al. · 1984Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: Constituents of orally-active Myristicaceous hallucinogens — analytical/ethnopharmacology studyView study →Reference 21Rucker JJ et al. · 2024RCTPhase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants — randomised controlled trialView study →}. Alkaloid content differs by orders of magnitude between species, regions and preparations ^{3Reference 3McKenna DJ et al. · 1984Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: Constituents of orally-active Myristicaceous hallucinogens — analytical/ethnopharmacology studyView study →}, so preparation match is the running caveat throughout.

0. Evidence by indication

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric, and I’ll keep honing the formula over time. Each indication name links down to its write-up.

Indication	Support	Rests on
Antidepressant (5-MeO-DMT)	███████░░░ 74%	Early human RCTs + systematic review of the marker alkaloid — but synthetic isolated 5-MeO-DMT by nasal spray/inhalation, not epeña. Human-tier evidence; efficacy still phase-2 stage, prep differs from the snuff.
Gastroprotective	███████░░░ 68%	Three independent rodent ulcer studies across V. surinamensis, V. oleifera, V. elongata; effect tracks phenolics/epicatechin. Resin/bark — the traditional prep. No human data.
Antioxidant	██████░░░░ 66%	Many in vitro + in vivo studies (lignans, resin) incl. atherosclerosis and nephropathy models. Well-replicated but preclinical; drives most downstream effects.
Anti-inflammatory	██████░░░░ 62%	Grandisin, flavones and a whole-bark extract active in rodent oedema/peritonitis models. Consistent, animal-only.
Antifungal	██████░░░░ 57%	Exceptionally well-documented ethnobotanically (resin on skin, ~14 groups); in vitro neolignan mechanism mapped but not fully resolved. Prep match good.
Antiparasitic	█████░░░░░ 47%	Leishmanicidal/trypanocidal neolignans in vitro; one in vivo mouse signal (42% inhibition). Mixed — several extracts inactive against intracellular forms.
Antiproliferative	████░░░░░░ 43%	Cytotoxic polyketides and essential oils vs. cancer cell lines; one in vivo colon-cancer xenograft. Cell-line dominated.
Antimalarial	███░░░░░░░ 28%	Single study; leaf essential oil (nerolidol) inhibits Plasmodium in vitro. Vapour/oil prep, constituent-level — not how the medicine is used.

1. Antidepressant (5-MeO-DMT)

The plant’s marker compound reaching the clinic, and the only human-tier evidence for epeña. Isolated 5-MeO-DMT — the principal Virola tryptamine — is in active development for treatment-resistant depression. A Phase 1 placebo-controlled ascending-dose RCT of the intranasal benzoate salt BPL-003 (1-12 mg) in 44 volunteers was well tolerated, rapidly absorbed (peak plasma ~8-10 min, half-life <27 min) and produced a “complete mystical experience” in 60% at 10-12 mg ^{21Reference 21Rucker JJ et al. · 2024RCTPhase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants — randomised controlled trialView study →}; a separate inhaled formulation (GH001) has run in healthy volunteers and treatment-resistant depression, with a rapid-assessment peak-experience scale developed to guide dosing ^{22Reference 22Reckweg JT et al. · 2025Clinical trialEvaluation of the peak experience scale as a rapid assessment tool for the strength of a psychoactive experience with 5-MeO-DMT — clinical studyView study →}. Systematic-review and regulatory analyses group 5-MeO-DMT with DMT as therapeutically promising for depression and substance-use disorders, while noting substantial risk of bias and no established efficacy yet ^{23,24Reference 23Wallace LM et al. · 2026Meta-analysisEfficacy of N, N-dimethyltryptamine (DMT) psychedelic therapy for substance misuse: A systematic review and meta-analysis — systematic review and meta-analysisView study →Reference 24Marazziti D et al. · 2026ReviewPsychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations — reviewView study →}. The molecule acts as a serotonergic (5-HT2A / 5-HT1A) agonist and is metabolised to the active tryptamine bufotenine ^{21Reference 21Rucker JJ et al. · 2024RCTPhase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants — randomised controlled trialView study →}.

Gap: The human data describe a purified synthetic molecule delivered by spray or inhalation under supervision — pharmacologically and legally distinct from the snuff, whose highly variable multi-alkaloid content ^{3Reference 3McKenna DJ et al. · 1984Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: Constituents of orally-active Myristicaceous hallucinogens — analytical/ethnopharmacology studyView study →} and forceful nasal use bear no resemblance to a titrated pharmaceutical. Efficacy for depression remains at the phase-2 stage, and none of this validates traditional epeña as a treatment.

2. Gastroprotective

The strongest botanical signal for Virola, and the one that best matches traditional use of the bark resin for stomach pain and ulcers. Ethanolic resin extract of Virola surinamensis (500 mg/kg p.o.) inhibited acidified-ethanol gastric lesions by ~95% in rodents and also cut indomethacin-, stress- and pylorus-ligature-induced ulceration by 31-45%, with epicatechin identified as the principal constituent ^{7Reference 7Hiruma-Lima CA et al. · 2009AnimalAntiulcerogenic action of ethanolic extract of the resin from Virola surinamensis Warb. (Myristicaceae) — in vivo rodent studyView study →}. Resin from Virola oleifera was gastroprotective at 10-100 mg/kg — comparable to lansoprazole — and is unusually phenol-rich (~82% polyphenols, with epicatechin and eriodictyol) ^{8Reference 8Pereira AC et al. · 2017AnimalGastroprotective activity of the resin from Virola oleifera — in vivo mouse studyView study →}. A hydroethanolic stem-bark extract of Virola elongata, standardised to gallic acid, catechin and rutin, reproduced the antiulcer effect in a third species ^{9Reference 9Almeida GVB et al. · 2019AnimalChemical characterization and evaluation of gastric antiulcer properties of the hydroethanolic extract of the stem bark of Virola elongata (Benth.) Warb — in vivo rodent studyView study →}. The activity is attributed to mucosal antioxidant/cytoprotective phenolics rather than acid suppression.

Gap: Entirely rodent, single-dose, prophylactic-model data; no healing-of-established-ulcer studies and no human trials. One report explicitly flags population-level toxicity concerns with the crude resin ^{7Reference 7Hiruma-Lima CA et al. · 2009AnimalAntiulcerogenic action of ethanolic extract of the resin from Virola surinamensis Warb. (Myristicaceae) — in vivo rodent studyView study →}.

3. Antioxidant

A broad and well-replicated preclinical theme that underlies most of Virola’s other activities. Aryltetralone lignans from Virola sebifera inhibited lipid peroxidation more effectively than α-tocopherol in vitro ^{10Reference 10Rezende KR et al. · 2005In vitroAntioxidant activity of aryltetralone lignans and derivatives from Virola sebifera (Aubl.) — in vitro studyView study →}, and the neolignan otobaphenol blocked iron/ascorbate-driven mitochondrial lipoperoxidation and delayed the permeability transition ^{11Reference 11Lemeshko VV et al. · 2003In vitroThe natural antioxidant otobaphenol delays the permeability transition of mitochondria and induces their aggregation — in vitro studyView study →}. The polyphenol-rich resin of V. oleifera shows strong DPPH/FRAP radical-scavenging, retained even when used to cap gold nanoparticles ^{12Reference 12Dos Santos Corrêa A et al. · 2018In vitroVirola oleifera-capped gold nanoparticles showing radical-scavenging activity and low cytotoxicity — in vitro studyView study →}. This antioxidant capacity translates into disease models: chronic resin administration reduced vascular lipid accumulation ~50% in atherosclerotic LDLr-knockout mice independent of cholesterol ^{13Reference 13Coutinho PN et al. · 2017AnimalChronic administration of antioxidant resin from Virola oleifera attenuates atherogenesis in LDLr — in vivo mouse studyView study →}, and protected against radiocontrast-induced nephropathy dose-dependently, outperforming N-acetylcysteine ^{14Reference 14Bôa IS et al. · 2015AnimalResin from Virola oleifera Protects Against Radiocontrast-Induced Nephropathy in Mice — in vivo mouse studyView study →}. A topical resin formulation also accelerated wound contraction while lowering tissue lipid/protein oxidation ^{15Reference 15Carvalho GR et al. · 2022AnimalDevelopment and Evaluation of Virola oleifera Formulation for Cutaneous Wound Healing — in vivo rat studyView study →}.

Gap: All in vitro or animal; “antioxidant activity in an assay” is a mechanism, not a proven clinical benefit. No human oxidative-stress endpoints have been tested.

4. Anti-inflammatory

Consistent activity in standard rodent models, traceable to both lignan and flavonoid fractions. The neolignan grandisin from Virola surinamensis reduced acetic-acid writhing dose-dependently and cut inflammatory-phase pain by ~60% and oil-induced ear oedema by ~36%, without sedation ^{16Reference 16Carvalho AA et al. · 2010AnimalAntinociceptive and antiinflammatory activities of grandisin extracted from Virola surinamensis — in vivo mouse studyView study →}. A flavone (titonine) and its derivatives from Virola michelli inhibited carrageenan paw oedema up to 68% and were dose-dependently analgesic ^{17Reference 17Carvalho JC et al. · 1999AnimalAnti-inflammatory activity of flavone and some of its derivates from Virola michelli Heckel — in vivo rat studyView study →}. A whole hydroethanolic extract of Virola elongata showed multitarget activity in LPS-peritonitis and croton-oil dermatitis, lowering TNF-α, IL-1β and nitric oxide while raising IL-10 in mice and macrophages ^{18Reference 18Di Serio BF et al. · 2024In vitroPhytochemistry and Evaluation of the Anti-Inflammatory Activity of the Hydroethanolic Extract of Virola elongata (Benth.) WarbView study →}.

Gap: Animal and cell models only; effective doses and the active fraction differ between studies, and one V. oleifera study found no effect on LPS-induced NO in chondrocytes ^{31Reference 31Francisco V et al. · 2021In vitroEvaluation of Virola oleifera activity in musculoskeletal pathologies: Inhibition of human multiple myeloma cells proliferation and combination therapy with dexamethasone or bortezomib — in vitro studyView study →} — the anti-inflammatory signal is real but not universal across species/preparations.

5. Antifungal

The best-documented ethnobotanical use of the resin, and the one with a plausible in vitro mechanism. Antifungal use of Virola exudate is recorded across roughly 14 Amazonian groups in four countries, applied topically to deep skin mycoses ^{6Reference 6Plotkin MJ · 1990ReviewVirola: a promising genus for ethnopharmacological investigation — review of antifungal ethnobotanyView study →}. Racemic 8.O.4′-neolignan alcohols characteristic of Virola inhibited hyphal growth of Neurospora crassa, apparently by interfering with cell-wall polymer synthesis, though β-glucan synthase inhibition did not fully explain the effect ^{19Reference 19Zacchino S et al. · 1998In vitroIn vitro studies on mode of action of antifungal 8.O.4’-neolignans occurring in certain species of Virola and related genera of Myristicaceae — in vitro studyView study →}. Broader antimicrobial screening of Virola surinamensis extracts supports activity against microbial panels ^{20Reference 20Costa ES et al. · 2008In vitroAntimicrobial activity of some medicinal plants of the Cerrado, Brazil — in vitro studyView study →}.

Gap: No controlled clinical antifungal trial despite the strong traditional record; the mechanistic in vitro work uses model fungi and isolated neolignans, and the active principle in the whole resin is not definitively pinned.

6. Antiparasitic

A recurring but inconsistent in vitro signal against Leishmania and Trypanosoma. Neolignans from Virola species and synthetic analogues were active against Leishmania donovani promastigotes, with the best (a sulphur-bridged analogue, not a natural product) giving 42% amastigote inhibition in mice ^{25Reference 25Barata LE et al. · 2000In vitroAnti-leishmanial activity of neolignans from Virola species and synthetic analogues — in vitro and in vivo studyView study →}. A hexane extract of Virola surinamensis leaves was leishmanicidal against promastigotes but inactive against the clinically relevant intracellular amastigotes ^{26Reference 26Veiga A et al. · 2017In vitroLeishmania amazonensis and Leishmania chagasi: In vitro leishmanicide activity of Virola surinamensis (rol.) warb — in vitro studyView study →}. Lignans from V. surinamensis twigs were the most trypanocidal fraction against Trypanosoma cruzi in vitro ^{27Reference 27Lopes NP et al. · 1998In vitroFlavonoids and lignans from Virola surinamensis twigs and their in vitro activity against Trypanosoma cruzi — in vitro studyView study →}, and a newly described lignan, (−)-5-demethoxygrandisin B, adds to the antileishmanial series ^{28Reference 28Paes SS et al. · 2023In vitroPaes SS, et al. (2023). (-)-5-Demethoxygrandisin B a New Lignan from Virola surinamensis (Rol.) Warb. Leaves: Evaluation of the Leishmanicidal Activity by In Vitro and In Silico Approaches — in vitro study. Pharmaceutics. 15(9). https://pubmed.ncbi.nlm.nih.gov/37765261/View study →}.

Gap: Activity is largely confined to extracellular parasite forms and isolated/synthetic compounds; efficacy against the intracellular stage that matters clinically is weak or absent, and no in vivo cure has been shown with a natural Virola preparation.

7. Antiproliferative

Cytotoxic activity against cancer cell lines, with one in vivo signal. Novel polyketides from Virola sebifera leaves were selectively cytotoxic to ovarian (OVCAR03) and multidrug-resistant (NCI-ADR) lines at 2-4 µg/mL ^{29Reference 29Denny C et al. · 2008In vitroAntiproliferative properties of polyketides isolated from Virola sebifera leaves — in vitro studyView study →}. Essential oils from Virola surinamensis bark and leaves inhibited human colon-carcinoma HCT116 cells in vitro and slowed HCT116 tumour growth in SCID mice, driving apoptosis and cell-cycle arrest ^{30Reference 30Anunciação TAD et al. · 2020In vitroIn vitro and in vivo inhibition of HCT116 cells by essential oils from bark and leaves of Virola surinamensis (Rol. ex Rottb.) Warb. (Myristicaceae) — in vitro and in vivo mouse studyView study →}. Resin from Virola oleifera strongly reduced multiple-myeloma cell viability via G2/M arrest and synergised with dexamethasone — but also antagonised bortezomib, a clear herb-drug-interaction warning ^{31Reference 31Francisco V et al. · 2021In vitroEvaluation of Virola oleifera activity in musculoskeletal pathologies: Inhibition of human multiple myeloma cells proliferation and combination therapy with dexamethasone or bortezomib — in vitro studyView study →}.

Gap: Cell-line dominated, with only a single xenograft; selectivity over normal cells is modest and the bortezomib antagonism means this is as much an interaction caution as a therapeutic lead.

8. Antimalarial

A single ethnobotany-driven study, and a preparation caveat that caps it. The Waiãpi of Amapá inhale vapour from Virola surinamensis leaves for malaria; the leaf essential oil (notably the sesquiterpene nerolidol) gave 100% inhibition of Plasmodium falciparum schizont development in vitro, apparently by blocking isoprenoid/glycoprotein biosynthesis ^{32Reference 32Lopes NP et al. · 1999In vitroAntimalarial use of volatile oil from leaves of Virola surinamensis (Rol.) Warb. by Waiãpi Amazon Indians — in vitro studyView study →}.

Gap: One in vitro study, using the volatile leaf oil — not the bark resin snuff and not a systemic dose. Nerolidol’s antimalarial activity is a genus-wide constituent effect, not evidence specific to how epeña is prepared or used.

Mechanisms

Mechanism	Drives	Key compounds
5-HT2A / 5-HT1A agonism (bufotenine = active 5-MeO-DMT metabolite)	psychoactivity; investigational antidepressant (isolated molecule)	5-MeO-DMT, N,N-DMT, bufotenine
lipid-peroxidation inhibition, mitochondrial protection, cytokine/NO ↓, fungal cell-wall interference	antioxidant, anti-inflammatory, antifungal, antiparasitic	grandisin, surinamensin, otobaphenol
radical scavenging, gastric mucosal cytoprotection	gastroprotective, antioxidant, vascular protection	epicatechin, eriodictyol, catechin, gallic acid, rutin
isoprenoid / glycoprotein-biosynthesis inhibition	antimalarial, antiproliferative	nerolidol

Clinical trials

No registered clinical trial exists for epeña or any whole-plant Virola preparation; the ~21 trials filed under “5-MeO-DMT” test synthetic, isolated 5-MeO-DMT (e.g. GH001 inhaled, BPL-003 intranasal) as an investigational antidepressant under medical supervision — credited to the marker alkaloid’s parent herb for scoring, but a purified pharmaceutical molecule, not the snuff.

Completed	Planned	Terminated	Preclinical
~21 (isolated synthetic 5-MeO-DMT; 0 whole-Virola)	—	—	~40

Last checked: July 2026.

Safety

Epeña is a potent tryptamine snuff whose principal alkaloid, 5-MeO-DMT, is one of the most powerful serotonergic psychedelics known; the prepared snuffs are intense, physically forceful and used only in traditional ceremonial contexts by experienced practitioners ^{1,4Reference 1Agurell S et al. · 1969Alkaloids in certain species of Virola and other South American plants of ethnopharmacologic interest — chemical isolation studyView study →Reference 4de Smet PA · 1985ReviewA multidisciplinary overview of intoxicating snuff rituals in the western hemisphere — reviewView study →}. The dominant pharmacological hazard is serotonin toxicity: 5-MeO-DMT combines dangerously with MAOIs and other serotonergic drugs, and the β-carbolines sometimes admixed with the snuff (or present in co-administered Banisteriopsis preparations) are themselves MAO-inhibiting and markedly potentiate the tryptamines ^{3,5,35Reference 3McKenna DJ et al. · 1984Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: Constituents of orally-active Myristicaceous hallucinogens — analytical/ethnopharmacology studyView study →Reference 5Ott J · 2001Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine — human self-experiment studyView study →Reference 35Rached G et al. · 2026Clinical trialSafety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data — review of drug interactionsView study →}. Fatalities have been reported for 5-MeO-DMT combined with MAOIs ^{35Reference 35Rached G et al. · 2026Clinical trialSafety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data — review of drug interactionsView study →}. Alkaloid content varies enormously between species, regions and preparations, so potency is unpredictable ^{1,3Reference 1Agurell S et al. · 1969Alkaloids in certain species of Virola and other South American plants of ethnopharmacologic interest — chemical isolation studyView study →Reference 3McKenna DJ et al. · 1984Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: Constituents of orally-active Myristicaceous hallucinogens — analytical/ethnopharmacology studyView study →}. DMT-class compounds — including DMT and 5-MeO-DMT — are controlled substances (Schedule I or equivalent) in most countries.

Notably, the plant’s non-alkaloidal extracts appear to have low intrinsic toxicity — a hydroethanolic Virola elongata bark extract was non-cytotoxic and non-genotoxic in vitro with a rodent NOAEL >1200 mg/kg ^{33Reference 33Carvalho MS et al. · 2024In vitroEvaluation of the toxicity of the hydroethanolic extract of the stem bark of Virola elongata (Benth.) Warb. in in vitro and in vivo models — in vivo rodent toxicology studyView study →} — but this does not extend to the alkaloid-rich ceremonial snuff, whose hazard is the tryptamine pharmacology rather than general phytotoxicity. A separate interaction signal comes from the oncology literature: Virola oleifera resin antagonised the chemotherapy drug bortezomib in a multiple-myeloma cell study ^{31Reference 31Francisco V et al. · 2021In vitroEvaluation of Virola oleifera activity in musculoskeletal pathologies: Inhibition of human multiple myeloma cells proliferation and combination therapy with dexamethasone or bortezomib — in vitro studyView study →}.

Herb–drug interactions have been assessed only for the specific mechanisms above: MAOI / serotonergic potentiation of 5-MeO-DMT is well documented and is the central concern ^{3,5,35Reference 3McKenna DJ et al. · 1984Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: Constituents of orally-active Myristicaceous hallucinogens — analytical/ethnopharmacology studyView study →Reference 5Ott J · 2001Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine — human self-experiment studyView study →Reference 35Rached G et al. · 2026Clinical trialSafety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data — review of drug interactionsView study →}; the lignan grandisin inhibits CYP1A2, 2C9, 3A4/5, 2D6 and 2E1 in vitro ^{34Reference 34Habenschus MD et al. · 2017In vitroIn Vitro Inhibition of Human CYP450s 1A2, 2C9, 3A4/5, 2D6 and 2E1 by Grandisin — in vitro studyView study →}; and the resin–bortezomib antagonism was seen in one cell study ^{31Reference 31Francisco V et al. · 2021In vitroEvaluation of Virola oleifera activity in musculoskeletal pathologies: Inhibition of human multiple myeloma cells proliferation and combination therapy with dexamethasone or bortezomib — in vitro studyView study →}. No broader human interaction screening exists.

Pregnancy & lactation

Avoid. No reproductive or lactation toxicology has been performed on epeña or any Virola preparation, so there is no evidence of safety in pregnancy or breastfeeding — treat this as “not assessed,” not as “safe.” Given that the active snuff is a potent serotonergic psychedelic with serious interaction and serotonin-toxicity risk, and that alkaloid content is unpredictable ^{3,35Reference 3McKenna DJ et al. · 1984Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: Constituents of orally-active Myristicaceous hallucinogens — analytical/ethnopharmacology studyView study →Reference 35Rached G et al. · 2026Clinical trialSafety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data — review of drug interactionsView study →}, avoidance in pregnancy and lactation is the only defensible position. (The rodent non-toxicity of the plant’s non-alkaloidal phenolic extracts ^{33Reference 33Carvalho MS et al. · 2024In vitroEvaluation of the toxicity of the hydroethanolic extract of the stem bark of Virola elongata (Benth.) Warb. in in vitro and in vivo models — in vivo rodent toxicology studyView study →} does not transfer to the alkaloid-rich snuff and should not be read as reassurance.)

References

1. Agurell S, Holmstedt B, Lindgren JE, Schultes RE (1969). Alkaloids in certain species of Virola and other South American plants of ethnopharmacologic interest — chemical isolation study. Acta Chem Scand. 23(3):903-16. https://pubmed.ncbi.nlm.nih.gov/5806312/
2. Holmstedt B (1965). Tryptamine derivatives in Epená, an intoxicating snuff used by some South American Indian tribes — ethnopharmacology study. Arch Int Pharmacodyn Ther. 156(2):285-305. https://pubmed.ncbi.nlm.nih.gov/5868939/
3. McKenna DJ, Towers GH, Abbott FS (1984). Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: Constituents of orally-active Myristicaceous hallucinogens — analytical/ethnopharmacology study. J Ethnopharmacol. 12(2):179-211. https://pubmed.ncbi.nlm.nih.gov/6521493/
4. de Smet PA (1985). A multidisciplinary overview of intoxicating snuff rituals in the western hemisphere — review. J Ethnopharmacol. 13(1):3-49. https://pubmed.ncbi.nlm.nih.gov/3887041/
5. Ott J (2001). Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine — human self-experiment study. J Psychoactive Drugs. 33(4):403-7. https://pubmed.ncbi.nlm.nih.gov/11824699/
6. Plotkin MJ, Schultes RE (1990). Virola: a promising genus for ethnopharmacological investigation — review of antifungal ethnobotany. J Psychoactive Drugs. 22(3):357-61. https://pubmed.ncbi.nlm.nih.gov/2286871/
7. Hiruma-Lima CA, et al. (2009). Antiulcerogenic action of ethanolic extract of the resin from Virola surinamensis Warb. (Myristicaceae) — in vivo rodent study. J Ethnopharmacol. 122(2):406-9. https://pubmed.ncbi.nlm.nih.gov/19162155/
8. Pereira AC, et al. (2017). Gastroprotective activity of the resin from Virola oleifera — in vivo mouse study. Pharm Biol. 55(1):472-480. https://pubmed.ncbi.nlm.nih.gov/27937036/
9. Almeida GVB, et al. (2019). Chemical characterization and evaluation of gastric antiulcer properties of the hydroethanolic extract of the stem bark of Virola elongata (Benth.) Warb — in vivo rodent study. J Ethnopharmacol. 231:113-124. https://pubmed.ncbi.nlm.nih.gov/30415060/
10. Rezende KR, et al. (2005). Antioxidant activity of aryltetralone lignans and derivatives from Virola sebifera (Aubl.) — in vitro study. Nat Prod Res. 19(7):661-6. https://pubmed.ncbi.nlm.nih.gov/16076635/
11. Lemeshko VV, et al. (2003). The natural antioxidant otobaphenol delays the permeability transition of mitochondria and induces their aggregation — in vitro study. Antioxid Redox Signal. 5(3):281-90. https://pubmed.ncbi.nlm.nih.gov/12880483/
12. Dos Santos Corrêa A, et al. (2018). Virola oleifera-capped gold nanoparticles showing radical-scavenging activity and low cytotoxicity — in vitro study. Mater Sci Eng C Mater Biol Appl. 91:853-858. https://pubmed.ncbi.nlm.nih.gov/30033320/
13. Coutinho PN, et al. (2017). Chronic administration of antioxidant resin from Virola oleifera attenuates atherogenesis in LDLr — in vivo mouse study. J Ethnopharmacol. 206:65-72. https://pubmed.ncbi.nlm.nih.gov/28502908/
14. Bôa IS, et al. (2015). Resin from Virola oleifera Protects Against Radiocontrast-Induced Nephropathy in Mice — in vivo mouse study. PLoS One. 10(12):e0144329. https://pubmed.ncbi.nlm.nih.gov/26674346/
15. Carvalho GR, et al. (2022). Development and Evaluation of Virola oleifera Formulation for Cutaneous Wound Healing — in vivo rat study. Antioxidants (Basel). 11(9). https://pubmed.ncbi.nlm.nih.gov/36139721/
16. Carvalho AA, et al. (2010). Antinociceptive and antiinflammatory activities of grandisin extracted from Virola surinamensis — in vivo mouse study. Phytother Res. 24(1):113-8. https://pubmed.ncbi.nlm.nih.gov/19468987/
17. Carvalho JC, et al. (1999). Anti-inflammatory activity of flavone and some of its derivates from Virola michelli Heckel — in vivo rat study. J Ethnopharmacol. 64(2):173-7. https://pubmed.ncbi.nlm.nih.gov/10197753/
18. Di Serio BF, et al. (2024). Phytochemistry and Evaluation of the Anti-Inflammatory Activity of the Hydroethanolic Extract of Virola elongata (Benth.) Warb. Stem Bark — in vivo mouse and in vitro study. Biology (Basel). 13(10). https://pubmed.ncbi.nlm.nih.gov/39452085/
19. Zacchino S, et al. (1998). In vitro studies on mode of action of antifungal 8.O.4’-neolignans occurring in certain species of Virola and related genera of Myristicaceae — in vitro study. J Ethnopharmacol. 62(1):35-41. https://pubmed.ncbi.nlm.nih.gov/9720609/
20. Costa ES, et al. (2008). Antimicrobial activity of some medicinal plants of the Cerrado, Brazil — in vitro study. Phytother Res. 22(5):705-7. https://pubmed.ncbi.nlm.nih.gov/18350520/
21. Rucker JJ, et al. (2024). Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants — randomised controlled trial. J Psychopharmacol. 38(8):712-723. NCT05347849. https://pubmed.ncbi.nlm.nih.gov/38616411/
22. Reckweg JT, et al. (2025). Evaluation of the peak experience scale as a rapid assessment tool for the strength of a psychoactive experience with 5-MeO-DMT — clinical study. Front Psychol. 16:1543640. https://pubmed.ncbi.nlm.nih.gov/40528856/
23. Wallace LM, et al. (2026). Efficacy of N, N-dimethyltryptamine (DMT) psychedelic therapy for substance misuse: A systematic review and meta-analysis — systematic review and meta-analysis. J Psychopharmacol. 2698811261430518. https://pubmed.ncbi.nlm.nih.gov/41967021/
24. Marazziti D, et al. (2026). Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations — review. Expert Opin Pharmacother. 27(5):451-461. https://pubmed.ncbi.nlm.nih.gov/41944071/
25. Barata LE, et al. (2000). Anti-leishmanial activity of neolignans from Virola species and synthetic analogues — in vitro and in vivo study. Phytochemistry. 55(6):589-95. https://pubmed.ncbi.nlm.nih.gov/11130669/
26. Veiga A, et al. (2017). Leishmania amazonensis and Leishmania chagasi: In vitro leishmanicide activity of Virola surinamensis (rol.) warb — in vitro study. Exp Parasitol. 175:68-73. https://pubmed.ncbi.nlm.nih.gov/28174103/
27. Lopes NP, et al. (1998). Flavonoids and lignans from Virola surinamensis twigs and their in vitro activity against Trypanosoma cruzi — in vitro study. Planta Med. 64(7):667-8. https://pubmed.ncbi.nlm.nih.gov/9810278/
28. Paes SS, et al. (2023). (-)-5-Demethoxygrandisin B a New Lignan from Virola surinamensis (Rol.) Warb. Leaves: Evaluation of the Leishmanicidal Activity by In Vitro and In Silico Approaches — in vitro study. Pharmaceutics. 15(9). https://pubmed.ncbi.nlm.nih.gov/37765261/
29. Denny C, et al. (2008). Antiproliferative properties of polyketides isolated from Virola sebifera leaves — in vitro study. Phytother Res. 22(1):127-30. https://pubmed.ncbi.nlm.nih.gov/17685388/
30. Anunciação TAD, et al. (2020). In vitro and in vivo inhibition of HCT116 cells by essential oils from bark and leaves of Virola surinamensis (Rol. ex Rottb.) Warb. (Myristicaceae) — in vitro and in vivo mouse study. J Ethnopharmacol. 262:113166. https://pubmed.ncbi.nlm.nih.gov/32730868/
31. Francisco V, et al. (2021). Evaluation of Virola oleifera activity in musculoskeletal pathologies: Inhibition of human multiple myeloma cells proliferation and combination therapy with dexamethasone or bortezomib — in vitro study. J Ethnopharmacol. 272:113932. https://pubmed.ncbi.nlm.nih.gov/33609728/
32. Lopes NP, et al. (1999). Antimalarial use of volatile oil from leaves of Virola surinamensis (Rol.) Warb. by Waiãpi Amazon Indians — in vitro study. J Ethnopharmacol. 67(3):313-9. https://pubmed.ncbi.nlm.nih.gov/10617066/
33. Carvalho MS, et al. (2024). Evaluation of the toxicity of the hydroethanolic extract of the stem bark of Virola elongata (Benth.) Warb. in in vitro and in vivo models — in vivo rodent toxicology study. J Ethnopharmacol. 319(Pt 1):117171. https://pubmed.ncbi.nlm.nih.gov/37714226/
34. Habenschus MD, et al. (2017). In Vitro Inhibition of Human CYP450s 1A2, 2C9, 3A4/5, 2D6 and 2E1 by Grandisin — in vitro study. Planta Med. 83(8):727-736. https://pubmed.ncbi.nlm.nih.gov/28073119/
35. Rached G, et al. (2026). Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data — review of drug interactions. CNS Drugs. 40(3):359-417. https://pubmed.ncbi.nlm.nih.gov/41546846/
36. Lotfi A, et al. (2026). 5-Methoxy-N,N-Dimethyltryptamine: Functional Safety Pharmacology and Video-EEG Assessment of a Short-Acting Serotonergic Psychedelic in Beagle Canines — in vivo animal safety study. Int J Toxicol. 10915818261419429. https://pubmed.ncbi.nlm.nih.gov/41618660/
37. González-Rodríguez M, et al. (2021). Pharmacological Extracts and Molecules from Virola Species: Traditional Uses, Phytochemistry, and Biological Activity — review. Molecules. 26(4). https://pubmed.ncbi.nlm.nih.gov/33546469/